Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISLB 2022 | Potential of liquid biopsy in lung cancer

Umberto Malapelle • 18 Oct 2022
ISLB 2022
Lung Cancer Non-Small Cell Lung Cancer

Umberto Malapelle, PhD, University of Naples Federico II, Naples, Italy, discusses current uses of liquid biopsy in clinical practice for patients with lung cancer, and explains the advantages of the complimentary approach of analysing tissue and liquid biopsy simultaneously. This interview took place at the International Society of Liquid Biopsy (ISLB) 2022 congress in Miami, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Speaker’s bureau for Boehringer Ingelheim, AstraZeneca, Roche, MSD, Amgen, Merck, BMS, Thermofisher, Biocartis.
Advisory role for Boehringer Ingelheim, MSD, Amgen, Merck, BMS, Diaceutics, Roche, Eli Lilly, Thermofisher, Janssen.

More from Umberto Malapelle

0:54
Liquid biopsy highlights from ELCC 2023
Umberto Malapelle • 27 Mar 2023
1:46
ctDNA approaches in lung cancer
Umberto Malapelle • 27 Mar 2023
1:23
Optimal positioning of liquid biopsies in the workup of patients with NSCLC
Umberto Malapelle • 27 Mar 2023
1:36
Unmet needs in liquid biopsy research
Umberto Malapelle • 18 Oct 2022

Related Videos

1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
0:57
STK-012-101: STK-012 in advanced solid tumors
Alexander Spira • 15 Mar 2024
3:34
FLAURA2: EGFRm dynamics in NSCLC treated with osimertinib
Pasi Jänne • 8 Apr 2024
0:54
FURVENT: furmonertinib in EGFR exon 20 mutant NSCLC
Alexander Spira • 15 Mar 2024
The content of VJOncology is intended for healthcare professionals